Download Free Sample
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Interleukin-12 Stimulators Market: Competitive Landscape, Pipeline, and Market Analysis 2023
Interleukin-12 Stimulators Market: Competitive Landscape, Pipeline, and Market Analysis 2023
Interleukin-12 (IL-12) is a heterodimeric cytokine with broad immunomodulatory properties that belongs to a larger family of proteins called IL-12-related cytokines. IL-12-related cytokines are produced by five independently regulated genes that homodimerize and heterodimerize to form seven secretory family members. These proteins have both overlapping and distinct biological properties and is predominantly produced by dendritic cells, monocytes, and macrophages, and to a lesser extent by B-cells. It has been identified as an immune cell stimulant that promotes T cell differentiation and proliferation and increases interferon-gamma production. Therefore, it has been associated with the regulation of CD4+ and CD8+ T cell differentiation, host defense, autoimmunity, immune recognition of tumor cells, alloimmunization, and host response to vaccination. Therefore, IL-12 functions as a potent regulator of immunity. The type of adaptive immune response is regulated by the innate response during the infection affected by the expression of IL-12 at that time. IL-12 Stimulators are being evaluated in various clinical settings for various indications. Extensive research is being conducted globally to discover new and novel molecules to be used as IL-12 Stimulators to be used for the treatment of many indications like as Mycobacterium infections. The development and launch of new products will thus increase the revenue of the market in the forecasted years.
A number of these stimulators are in the market while many are in ongoing clinical trials. 46 companies have about 44 products in their pipelines with 34 products in various stages of clinical trials – 1 in Phase 3, 19 in Phase 2 and 24 in Phase 1 of the clinical trials.
Drugs in the Pipeline of IL-12 Stimulators
Clinical Activity and Developments of IL-12 Stimulators
As of July 2023, 46 companies have approximately 44 products for 34 diseases. For these diseases, 61 trials are being conducted by players globally. For instance,
|
Molecule name |
Number of studies |
|
rocakinogene sifuplasmid (INO-9012) |
14 |
|
PDS0301 |
12 |
|
Tavo (tavokinogene telsaplasmid) |
11 |
|
Ad-RTS-hIL-12 |
8 |
|
IMNN-001 |
7 |
IL-12 Stimulators are being evaluated in the clinical trials since many years for the treatment of numerous malignancies and it is being evaluated as a monotherapy and/or in combination with other drugs. IL-12 has shown to show antitumor response, against Cutaneous T-cell Lymphoma and Non-Hodgkin’s Lymphoma. IL-12 administration is more effective and safer if delivered and maintained in the tumor through the use of novel delivery technologies as it generates systemic antitumor immunity from a locally initiated immune response. IL-12 deficiency has been associated with tumor growth, urinary bladder diseases, asthma, airway hyperresponsiveness, viral infections like AIDS, Chronic Hepatitis and other diseases. Therefore, these are ana important target for many disorders and their optimum level is important for normal physiological functioning of the body.
According to the Asthma and Allergy Foundation of America (AAFA), approximately 26 million individuals in the United States will have asthma in 2022, with 21 million being adults over the age of 18 and 4.8 million being children under the age of 18. Also, the prevalence of Alzheimer's disease in the United States in 2019 was 7.3%. According to the American Lung Association report, about 1.8 billion global population are infected with Tuberculosis while 10 million people have active Tuberculosis globally. According to the National Brain Tumor Society 2023 report, Glioblastoma accounts for more than 50% of primary malignant brain tumor with more than 14,490 people expected to be diagnosed with Glioblastoma in the USA in 2023.
Latin America
Europe
Asia Pacific
Middle East
North America
Download Free Sample Report
Currently, no IL-12 Stimulators have been approved by the FDA.
These are being evaluated in trials for the treatment of Cutaneous T-cell Lymphoma, Non-Hodgkin’s Lymphoma, Glioblastoma, Asthma Bacterial infections and others.
PDS Biotech, OncoSec Medical Inc, Alaunos Therapeutics, Imunon Inc and AstraZeneca are some of the major market players for IL-12 Stimulators.
Rising incidence of diseases improvement in technologies, development of new treatment lines in the market and rising incidence of various types of diseases like Cutaneous T-cell Lymphoma, Glioblastoma, Asthma, Mycobacterium infections and others are the key opportunities for IL-12 Stimulators in the market.
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.